Screener
ImmunityBio, Inc. IBRX Unpaid offering costs included in accounts payable and accrued expenses
Unpaid offering costs included in accounts payable and accrued expenses at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s unpaid offering costs included in accounts payable and accrued expenses?
- ImmunityBio, Inc. (IBRX) reported unpaid offering costs included in accounts payable and accrued expenses of $136K in Q1 2026.
- What is the long-term trend for ImmunityBio, Inc.'s unpaid offering costs included in accounts payable and accrued expenses?
- Over 2 years (2022 to 2025), ImmunityBio, Inc.'s unpaid offering costs included in accounts payable and accrued expenses has grown at a 2.8% compound annual growth rate (CAGR), from $277K to $293K.
- What does unpaid offering costs included in accounts payable and accrued expenses mean?
- This represents costs incurred in connection with equity or debt offerings that have been accrued but not yet paid in cash. It provides visibility into the deferred cash impact of capital-raising activities.
Ask your AI about ImmunityBio, Inc.'s unpaid offering costs included in accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude